Sounds like the kids organised a nice welcome home party for you, Chookman - welcome back ;) _________
2012 is a long way from over yet, jaybay - I don't understand why so many here have already given up on this year. At times I've assumed that all the negative jibes was just seeking the opportunity to load up, however the sp doesn't really support this theory.
Big news in my view will arrive without warning any day now, and the month of October is certainly no stranger to news flow coming from OBJ...
The vibe I'm getting from the company is a stark contrast to many comments I've been reading on here - So I think I'll stick to the company's message. As for the theory of insider trading as any indication for the arrival of material news, I can accept this might be the case for 99% of the stocks traded on the ASX but the last time I checked D4DR Technology Partnerships only have 202 shares and are not publicly traded so Im not sure how those working with OBJ's International Partnering Manager are going to make the connection... but good luck to them if they try ;)
The Company’s drug delivery platforms include: - Powered electromagnetic delivery systems for use in devices and appliances - Motion-activated magnetic micro-arrays for use in consumer products and devices - Materials-based arrays for use in cosmetic and drug patch applications.
____________________
The Company acts as technology and innovation partner to a number of the world’s leading medical, consumer products, healthcare and cosmetic companies
____________________
The announcement of the Joint Development Agreement with Procter and Gamble, the world’s largest consumer goods company and the expansion of programs with GlaxoSmithKline, one of the world’s largest pharmaceutical companies were major accomplishments...
____________________
The Company has been working with a number of the teams at P&G’s Cincinnati facility for some time culminating in a funded multi-product development...
____________________
During the period, the Company showed partner companies commercially significant levels of product performance enhancement in the Oral health, cosmetic, skin care, analgesic, pharmaceutical and industrial fields.
____________________
OBJ’s FIM technology had a substantial effect on the bioavailability of certain drugs following application by Micro-needles
____________________
The OBJ technology platform has also been further extended beyond ETP and Dermaportation, and now includes a programmable applicator device, a new patent applied "popper" for single dose applications, and an integrated applicator combining magnetic array and microneedle technology.
____________________
A GSK funded study program is currently under negotiation.
____________________
The Company’s powered technology, known as eSkin, was expanded to include web based personalised skin care capabilities which have been enthusiastically received by our partners and negotiations are ongoing with one potential partner.
These represent a couple of words delivered from only one announcement... P&G clinical trials should also be commencing soon...
OBJ Price at posting:
1.4¢ Sentiment: LT Buy Disclosure: Held
(20min delay)